Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

被引：0

作者：

Carla Damaschin

Helen Goergen

Stefanie Kreissl

Annette Plütschow

Frank Breywisch

Stephan Mathas

Julia Meissner

Martin Sökler

Max S. Topp

Vladan Vucinic

Andreas Zimmermann

Bastian von Tresckow

Michael Fuchs

Andreas Engert

Peter Borchmann

Dennis A. Eichenauer

机构：

[1] University of Cologne,First Department of Internal Medicine

[2] Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf,German Hodgkin Study Group (GHSG)

[3] University Hospital Cologne,Department of Hematology

[4] Oncology and Palliative Care,Department of Hematology

[5] Klinikum Ernst von Bergmann,Fifth Department of Internal Medicine

[6] Oncology and Tumor Immunology,Second Department of Internal Medicine

[7] Charité-Universitätsmedizin Berlin,Second Department of Internal Medicine

[8] Max-Delbrück-Center for Molecular Medicine,Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology

[9] Berlin,Department of Internal Medicine III

[10] and Experimental and Clinical Research Center (ECRC),Department of Hematology and Stem Cell Transplantation, West German Cancer Center

[11] University Hospital Heidelberg,undefined

[12] University Hospital Tübingen,undefined

[13] University Hospital Würzburg,undefined

[14] University Hospital Leipzig,undefined

[15] University Hospital Munich,undefined

[16] University Hospital Essen,undefined

[17] University of Duisburg-Essen,undefined

来源：

Leukemia | 2022年 / 36卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：580 / 582

页数：2

共 50 条

[1] Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Damaschin, Carla
Goergen, Helen
Kreissl, Stefanie
Pluetschow, Annette
Breywisch, Frank
Mathas, Stephan
Meissner, Julia
Soekler, Martin
Topp, Max S.
Vucinic, Vladan
Zimmermann, Andreas
von Tresckow, Bastian
Fuchs, Michael
Engert, Andreas
Borchmann, Peter
Eichenauer, Dennis A.
LEUKEMIA, 2022, 36 (02) : 580 - 582
[2] Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study
Chen, Robert W.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (02) : 9 - 10
[3] Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study
Borchmann, Peter
Eichenauer, Dennis A.
Pluetschow, Annette
Haverkamp, Heinz
Kreissl, Stefanie
Fuchs, Michael
Soekler, Martin
Hellmuth, Johannes C.
Meissner, Julia
Mathas, Stephan
Behringer, Karolin
Dietlein, Markus
Kobe, Carsten
Diehl, Volker
Engert, Andreas
BLOOD, 2015, 126 (23)
[4] TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY
Borchmann, P.
Eichenauer, D.
Pluetschow, A.
Kreissl, S.
Fuchs, M.
Soekler, M.
Engel, N.
Mathas, S.
Behringer, K.
Kobe, C.
Dietlein, M.
Diehl, V.
Engert, A.
HAEMATOLOGICA, 2014, 99 : 497 - 498
[5] ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis
Vijenthira, Abi
Cheung, Matthew C.
Phua, Chai Wye
Chan, Kelvin
Graczyk, Joanna
Buckstein, Rena
Prica, Anca
BLOOD, 2016, 128 (22)
[6] Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
Connors, Joseph M.
Ansell, Stephen M.
Fanale, Michelle
Park, Steven I.
Younes, Anas
BLOOD, 2017, 130 (11) : 1375 - 1377
[7] Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma
Niitsu, Nozomi
Okamoto, Masataka
Tomita, Naoto
Aoki, Sadao
Tamaru, Jun-ichi
Miura, Ikuo
Hirano, Masami
LEUKEMIA & LYMPHOMA, 2006, 47 (09) : 1908 - 1914
[8] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Rueda, Antonio
Armand, Philippe
Trneny, Marek
Feldman, Tatyana A.
Ansell, Stephen M.
Provencio, Mariano
Jaeger, Ulrich
Cohen, Jonathon B.
Savage, Kerry J.
Willenbacher, Wolfgang
Sacchi, Mariana
Sumbul, Anne
Domenech, Eva Domingo
BLOOD, 2017, 130
[9] Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
Engert, Andreas
Diehl, Volker
Franklin, Jeremy
Lohri, Andreas
Doerken, Bernd
Ludwig, Wolf-Dieter
Koch, Peter
Haenel, Mathias
Pfreundschuh, Michael
Wilhelm, Martin
Truemper, Lorenz
Aulitzky, Walter-Erich
Bentz, Martin
Rummel, Mathias
Sezer, Orhan
Mueller-Hermelink, Hans-Konrad
Hasenclever, Dirk
Loeffler, Markus
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4548 - 4554
[10] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group (GHSG)
Eich, H.
Engert, A.
Haverkamp, H.
Staar, S.
Kriz, J.
Engenhart-Cabillic, R.
Lukas, P.
Willich, N.
Diehl, V.
Mueller, R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S3 - S4

← 1 2 3 4 5 →